CompanyGraph
Makes knee and hip implants that only work fully inside its own Rosa robotic surgery system.
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
- FinancialsAltman Z-Score: grey zone
- Interpretations3 currently firing — 1 · 2
What this company is and how it runs — written from structure, not news.
Zimmer Biomet makes titanium and cobalt-chromium joint implants that are co-designed with its Rosa robotic surgery platform, so each implant geometry is only fully validated when guided by Rosa's specific positioning software — not by any robot in general. Because the FDA issues clearance per implant design against the exact guidance parameters used in clinical trials, a competitor cannot take Rosa hardware or copy the implant shape and claim the same validation history; the regulatory approval is tied to the combination, not the parts. That clinical record takes three to seven years to build for each geometry, which means the number of implants Zimmer can bring to market at any moment is capped by how many parallel FDA pathways are running at once, and a surgeon trained on Rosa's instrumentation develops muscle memory for geometries that have no equivalent anywhere else. The arrangement holds as long as the FDA continues clearing new geometries under the existing predicate pathway — if it were to reclassify the Rosa-implant combination as a new device class requiring a fresh approval process, every geometry currently in the portfolio would need to restart that multi-year clinical clock from the beginning.
How does this company make money?
The company charges hospitals and ambulatory surgery centers for each individual knee or hip implant sold. Separately, it earns money when a hospital buys a Rosa robotic system outright, and then again through ongoing software licensing fees for the surgical planning modules that run on that system.
What makes this company hard to replace?
Surgeons must complete Rosa robotic training and build muscle memory with instrumentation sets that do not transfer to any competing implant system — starting over means retraining from scratch. Hospitals that bought a Rosa platform have it on a multi-year depreciation schedule, which means switching to a different robotic-implant combination before that investment is recovered is a difficult financial decision.
What limits this company?
The company can only release a new implant geometry after years of clinical trials — typically three to seven — and the FDA approves each shape separately. That means the number of implant designs the company can sell at any moment is capped by how many approval processes are running and how close each one is to finishing.
What does this company depend on?
The company cannot operate without titanium alloy suppliers for implant bodies, cobalt-chromium feedstock for bearing surfaces, hydroxyapatite coating technologies for bone integration, FDA 510(k) clearances for each knee and hip model, and ISO 13485 quality certifications for its manufacturing facilities.
Who depends on this company?
Orthopedic surgeons performing total knee and hip replacements would lose access to the specific implant shapes and instrument sets they trained on. Ambulatory surgery centers doing joint procedures would face shortages of the coordinated implant-and-instrument kits. Hospital operating rooms would lose the Rosa robotic platform along with its surgical planning software.
How does this company scale?
Once an implant design clears the FDA and its manufacturing process is validated, the tooling and quality systems can be replicated across facilities, spreading compliance costs over a larger number of units. What does not scale easily is surgeon adoption — each orthopedic surgeon has to go through Rosa training personally, build hands-on confidence with the specific instrumentation, and repeat that process for every implant design they want to use.
What external forces can significantly affect this company?
Medicare reimbursement rates for joint replacement procedures set a ceiling on what hospitals will pay for implants, and any cuts to those rates squeeze purchasing budgets directly. Aging populations in developed markets mean more people need joint replacements, but most of them are Medicare patients, so higher volumes come bundled with price pressure. Medical device tax rules in different countries add cost on top of implant pricing.
Where is this company structurally vulnerable?
If the FDA decides the Rosa-implant combination counts as an entirely new device class requiring a more demanding approval process called de novo PMA rather than the existing 510(k) path, every implant design in the current lineup would need a fresh round of multi-year clinical trials. That would erase the regulatory head start that makes the whole closed system hard to compete with.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Close In Upper Portion Of Recent Range, Bollinger Bands, And RSI
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Depreciation Intensity
Three depreciation observations align at elevated readings: depreciation is large relative to operating cash flow (industry-benchmarked), depreciation is a large share of EBITDA, and accumulated depreciation is a large share of gross properties. Together they describe a depreciation-heavy profile across three denominators.
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.